title: Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
abstract: There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.
authors.affiliation: MRC/NCRI, UK. j.ledermann@ctc.ucl.ac.uk
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Ledermann
authors.forename: Christian
authors.initials: C
authors.lastname: Marth
authors.forename: Mark S
authors.initials: MS
authors.lastname: Carey
authors.forename: Michael
authors.initials: M
authors.lastname: Birrer
authors.forename: David D L
authors.initials: DD
authors.lastname: Bowtell
authors.forename: Stan
authors.initials: S
authors.lastname: Kaye
authors.forename: Iain
authors.initials: I
authors.lastname: McNeish
authors.forename: Amit
authors.initials: A
authors.lastname: Oza
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.forename: Gordon
authors.initials: G
authors.lastname: Rustin
authors.forename: Frederick B
authors.initials: FB
authors.lastname: Stehman
authors.forename: David
authors.initials: D
authors.lastname: Gershenson
authors.forename: Gillian
authors.initials: G
authors.lastname: Thomas
authors.forename: Els
authors.initials: E
authors.lastname: Berns
authors.forename: Antonio
authors.initials: A
authors.lastname: Casado
authors.forename: Nelleke
authors.initials: N
authors.lastname: Ottevanger
authors.forename: Felix
authors.initials: F
authors.lastname: Hilpert
authors.forename: Byoung-Gie
authors.initials: BG
authors.lastname: Kim
authors.forename: Aikou
authors.initials: A
authors.lastname: Okamoto
authors.forename: Monica
authors.initials: M
authors.lastname: Bacon
authors.forename: Henry
authors.initials: H
authors.lastname: Kitchener
authors.forename: Gavin C E
authors.initials: GC
authors.lastname: Stuart
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends; D032921:Consensus; D055808:Drug Discovery / Q000639:trends; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents